Entering text into the input field will update the search result below

Biotech Forum: The Week Ahead

Apr. 02, 2018 10:35 AM ETCLVSQ, MRK, OMER, PCRX18 Comments


  • The markets open up second quarter trading today after posting a down first quarter of 2018.
  • It is a relatively light FDA calendar this week with some important PDUFA dates to take note of.
  • We look at what lies ahead for the biotech sector this week as well as post a 'stock watch' overview on Omeros in the paragraphs below.

One cannot be brave who has no fear." - Marissa Meyer, Renegades

It was another tumultuous week for the market. The equity market turned very volatile in the first quarter of this year after being in non-stop rally mode since the presidential election, as we closed out the opening stanza of the year on a high note, with the Dow climbing some 250 points Thursday before the long holiday weekend.

Overall, the market posted slight gains for the week. The last hour of the trading day continues to be the most volatile one of the day as passive ETFs and funds re-balance on a daily basis.

The biotech indices moved up and down throughout the week but largely ended the week where they began. Hopefully, when first quarter earnings results start to hit the wires in a few weeks, they will help to stabilize the market.

There are no major healthcare conferences on the agenda this week that I am aware of. There are a few items on the FDA calendar, however.

Keytruda from Merck (MRK) has a supplemental BLA (Biologic License Application) to be approved to treat Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma on Tuesday.

EXPAREL from Pacira Pharmaceuticals (PCRX) has a Friday supplemental NDA date with the FDA seeking approval as a single-dose injection femoral nerve block for total knee arthroplasty surgery. An Ad Comm Panel voted 6-4 against recommending for approval in mid-February. Getting the green light from the FDA is therefore 'iffy' at best.

Finally, also on Friday, Clovis Oncology (CLVS) hopes to see its compound Rucaparib get FDA approval to treat ovarian cancer patients with a BRCA-like mutation. Phase 3 data was released last June and met its primary endpoint.

All governments suffer a recurring problem: Power attracts pathological personalities. It is not that power

This article was written by

Bret Jensen profile picture
Finding tomorrow's big winners in the lucrative biotech sector

Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha. It is the fourth most subscribed to investment service offered through the Marketplace on SeekingAlpha.com. Our service offers a model-20 stock portfolio as well as the most active Live Chat on the Marketplace. This is where scores of seasoned biotech investors trade news and investment ideas back and forth throughout the trading day.

• • •

Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.

• • •

Learn more about Bret Jensen's Marketplace Offerings:

The Insiders Forum | The Biotech Forum | Busted IPO Forum

Analyst’s Disclosure: I am/we are long CLVS, OMER. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.